The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
High dimensional mapping of temporal evolution within the marrow microenvironment in response to FLT3 inhibitor therapy.
 
Matthew Newman
No Relationships to Disclose
 
Sunil K. Joshi
No Relationships to Disclose
 
Daniel Bottomly
No Relationships to Disclose
 
Shannon McWeeney
No Relationships to Disclose
 
Brian J. Druker
Leadership - Amgen; Vincera Pharma/Vincerx Pharma
Stock and Other Ownership Interests - Amgen; Blueprint Medicines; CTI; Enliven Therapeutics; GRAIL; MolecularMD; Third Coast Therapeutics; Vincera Pharma/Vincerx Pharma
Honoraria - Aptose Biosciences; Cepheid
Consulting or Advisory Role - Aileron Therapeutics; Aptose Biosciences; Blueprint Medicines; Celgene; Cepheid; Enliven Therapeutics; Gilead Sciences; GRAIL; Iterion Therapeutics; MolecularMD; Nemucore Medical Innovations; Novartis; Patient True Talk; RUNX1 Research Program; RUNX1 Research Program; Therapy Architects; Third Coast Therapeutics; VBL Therapeutics; Vincera Pharma/Vincerx Pharma; Vivid Biosciences
Research Funding - Bristol-Myers Squibb (Inst); Enliven Therapeutics (Inst); Novartis (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Merck; OHSU patents
Travel, Accommodations, Expenses - Amgen; Amgen
(OPTIONAL) Uncompensated Relationships - Beat AML; Burroughs Wellcome Fund; CureOne
 
Evan Lind
Research Funding - Amgen; Celgene; Ikena Oncology; Janssen; Monojul
 
Elie A. Traer
Consulting or Advisory Role - Abbvie; Agios; Astellas Pharma; Daiichi Sankyo
Research Funding - Incyte